Background Linezolid was recently re‐classified as a Group A drug by the World Health
Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and …

Little is known about the impact of comorbidities on multidrug resistant (MDR) and
extensively drug resistant (XDR) tuberculosis (TB) treatment outcomes. We aimed to …

Background Tuberculosis (TB) treatment is lengthy and complicated and patients often
develop chronic lung disease. Recent attention has focused on host-directed therapies …

Background. Resistance to second-line drugs develops during treatment of multidrug-
resistant (MDR) tuberculosis, but the impact on treatment outcome has not been determined …

Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR
TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had …

Abstract Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging
because it relies on second-line drugs that are less potent and more toxic than those used in …

In response to the urgent need to encounter infection diseases, and upon increasing
concerns about the devastating effects of tuberculosis (TB), the promising thiazolidin-4-one …

Background Ukraine is among ten countries with the highest burden of multidrug-resistant
TB (MDR-TB) worldwide. Treatment success rates for MDR-TB in Ukraine remain below …

Objectives The aim of this study was to retrospectively analyze the clinical outcome and the
risk factors associated with poor outcome of MDR-TB patients receiving standardized …

In high tuberculosis (TB)-burden countries such as China, the diagnosis of multidrug-
resistant tuberculosis (MDR-TB) using conventional drug susceptibility testing (DST) takes …